Cardiopulmonary exercise testing and the 2022 definition of pulmonary hypertension

17 June 2024

Dirk Habedank, Till Ittermann, Sabine Kaczmarek, Beate Stubbe, Alexander Heine, Anne Obst, Ralf Ewert

https://doi.org/10.1002/pul2.12398

Abstract

Parameters of cardiopulmonary exercise testing significantly discriminate between healthy subjects and patients with pulmonary hypertension (PH), also according to the new 2022 definition of pulmonary hypertension (mean pulmonary arterial pressure mPAP > 20 mmHg). The cut-offs indicating on PH were peakVO2 ≤ 16.7 mL/min/kg (Youden-Index YI = 0.79), petCO2@AT ≤ 34 mmHg (YI = 0.67), and VE/VCO2@AT ≤ 30 (YI = 0.76).

Read the full research letter

Share:

Other materials on this topic

Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view

More from Pulmonary Circulation

Show more details

A collection of up-to-date abstracts from our premier, international, peer-reviewed, medical research journal dedicated exclusively to pulmonary circulation and pulmonary vascular disease. 

Pulmonary vascular disease, environmental pollution, and climate change
Human pulmonary microvascular endothelial cells respond to DAMPs from injured renal tubular cells
Creating a digital approach for promoting physical activity in pediatric pulmonary hypertension: A framework for future interventions
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary disease without pulmonary hypertension
A systematic review of the impact of pulmonary thromboendarterectomy on health-related quality of life
Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A global cross-sectional scientific survey (CLARITY)
Ruptured pulmonary arteriovenous fistula causing hemothorax in a patient with hereditary hemorrhagic telangiectasia: A case report
A perfectly imperfect engine: Utilizing the digital twin paradigm in pulmonary hypertension
Nonsurgical treatment of a patient with decompensated right ventricular failure due to chronic thromboembolic pulmonary hypertension with proximal clot location—A case report
The European Voice of the Patient living with pulmonary hypertension associated with interstitial lung disease: Diagnosis, symptoms, impacts, and treatments
Excess healthcare resource utilization and costs for commercially insured patients with pulmonary arterial hypertension: A real-world data analysis
Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP)
Association of mildly elevated pulmonary vascular resistance with major cardiovascular events in pulmonary hypertension and chronic kidney disease: A retrospective cohort analysis
Evaluating the technical use of a Fitbit during an intervention for patients with pulmonary arterial hypertension with quality of life as primary endpoint: Lessons learned from the UPHILL study
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studies